OSUR — OraSure Technologies, Inc.
OSUR dilution and offerings
- Float: 65.3M shares
$3.94-3.43%
Last close: · regular session
Last 60 sessions
Float: 65.3M shares. Latest SEC filing: 10-Q on Aug 7, 2026. OSUR closed at $3.94 (-3.43%) on Oct 30, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for OSUR in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Medical - Instruments & Supplies
- Country: US
- Exchange: NASDAQ
- Employees: 501
- Website: https://www.orasure.com
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Latest SEC filings for OSUR
Latest OSUR news
- OraSure Technologies rejoint la Coalition mondiale contre la drépanocytose afin de favoriser l’accès à un diagnostic plus précoce et aux soins Read article
- OraSure Technologies تنضم إلى التحالف العالمي لمكافحة مرض الخلايا المنجلية لتعزيز فرص التشخيص المبكر والحصول على الرعاية الصحية Read article
- OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.